Melanoma Matters

Ep 28: RELATIVITY 048

Listen Later

Summary

Hosts Sapna Patel and James Larkin discuss what they're currently watching on tv & streaming services. (Spoiler: Eric Cartman on Ozempic)

The main conversation delves into the Relativity 48 study of triple immune checkpoint inhibition presented at ASCO 2024. The hosts discuss the study's design, patient characteristics, safety profile, and efficacy results, highlighting the importance of understanding the implications of this new treatment regimen. They also explore future directions for research and the potential impact on clinical practice.


Keywords

Relativity 48, melanoma, triple therapy, immune checkpoint inhibitors, safety, efficacy, ASCO 2024


Takeaways

  • The Relativity 48 study is a significant advancement in melanoma treatment.
  • Triple therapy includes nivolumab, rlatlimab, and ipilimumab.
  • Safety profile shows 100% of patients experienced adverse events.
  • Median PFS has not been reached, indicating ongoing efficacy evaluation.
  • The objective response rate was reported at 59%.
  • Patient selection may introduce bias in treatment outcomes.
  • Future studies are needed to confirm safety and efficacy in broader populations.
  • LAG3 blockade's dose responsiveness remains an open question.
  • Community oncologists are sensitive to toxicity issues in treatment.
  • The study has not yet been published, awaiting further analysis.


    • Titles

    Relativity 48: What We Learned from ASCO 2024

    Triple Therapy for Melanoma: Safety and Efficacy Insights


    Sound Bites

    "100% of patients had an adverse event."

    "Median PFS has not been reached yet."

    "The objective response rate was 59%."


    Chapters

    00:00 Introduction and TV Preferences

    02:55 Overview of the Relativity 48 Study

    09:20 Safety Profile of the Triple Therapy

    15:39 Objective Response Rate and Independent Central Review

    18:23 Progression-Free Survival and Follow-Up

    24:00 Exploring Higher Doses of Ipilimumab and Future Trials

    31:45 Fact Check


    ...more
    View all episodesView all episodes
    Download on the App Store
    Melanoma MattersBy Melanoma Matters Pod
    • 3.7
    • 3.7
    • 3.7
    • 3.7
    • 3.7

    3.7

    3 ratings

    More shows like Melanoma Matters

    View all
    Pod Save America by Pod Save America

    Pod Save America

    87,964 Listeners